Inhibikase Therapeutics Inc
NASDAQ:IKT
Inhibikase Therapeutics Inc
Revenue
Inhibikase Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
Revenue
$260.5k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Inhibikase Therapeutics Inc's Revenue?
Revenue
260.5k
USD
Based on the financial report for Dec 31, 2023, Inhibikase Therapeutics Inc's Revenue amounts to 260.5k USD.
What is Inhibikase Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
-42%
Over the last year, the Revenue growth was 117%. The average annual Revenue growth rates for Inhibikase Therapeutics Inc have been -28% over the past three years , -42% over the past five years .